The drug Huvemek, which contains the active ingredient ivermectin, is of great interest in hundreds of pharmacies across the country, according to a BLIC reporter. This happens a few days after the Medicines Executive Agency allows the drug to be sold free of charge. This means that yet another Balkan-based EU nation has authorized ivermectin at least on an emergency basis for an early onset treatment for mild to moderate COVID-19. TrialSite has reported that Slovakia and Macedonia have also authorized use of this generic drug to treat COVID-19 vases.
Health authorities there have accepted the position that this drug has an exceptional effect when used in the early stages of treatment after infection with coronavirus infection. It is no accident that luminaries under the direction of Assoc. Prof. Georgi Popov and Professor Ivo Petrov “Huvemek” gave a positive rating.
The Huvemek Marketing Authorization Holder is Huvepharma EOOD. Late last month, the company announced that it had conducted a large-scale clinical trial of ivermectin’s use in the treatment of COVID-19. This is the first multi-center, randomized, double-blind, placebo-controlled phase 2 study in the European Union. The tests were carried out between May and October 2020. The study started immediately after the first reports of an in vitro effect of ivermectin against the SARS-COV-2 virus in April 2020
Ivermectin Momentum Growing
There is strong evidence that ivermectin blocks the virus’ transport protein from entering the nucleus and makes it difficult to multiply. The drug has helped tens of thousands of men and women recover from COVID.
Ivermectin is currently approved for human use in the United States, France, Austria, Germany, Denmark, the Netherlands, and other countries.